	Enzyme replacement therapy
Hunter syndrome
Mucopolysaccharidosis type II
Treatment recommendations
Idursulfase
	MPS II
patients
severe
severe disease
disease
MPS II generally
age
GAGs
ERT
recessive disease
complications
progressive
CNS involvement
diagnosis
clinical phenotype
treatment
infusion-related reactions
disorder
common
due
severe airway obstruction
enzyme replacement therapy
challenges
idursulfase
weekly
cell therapy
involvement results
clinical course
life
improvement
death
joint contractures
placebo-controlled trial
normal
upper airway
early developmental milestones
screening tests
Xlinked
rhinorrhoea
attenuated form
reactions
infusion
gene
joints
spleen
adverse event
study

